Sho Ikeda

12PUBLICATIONS
14CO-AUTHORS
Molecular targetsMedical mycologyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Nov 14, 2025
NF-κB Is a Potential Therapeutic Target for Histone Deacetylase Inhibitor-Resistant Cutaneous T-Cell Lymphoma.

Yuto Takahashi, Akihiro Kitadate, Sayaka Iwama

|Apr 22, 2025
Multiple myeloma with 1q gain/amplification exhibits reduced CD38 expression via interleukin-6 receptor overexpression.

Wataru Kuroki, Akihiro Kitadate, Yuto Takahashi

|Apr 11, 2025
c-FOS Confers Stem Cell-like Features to Multiple Myeloma Cells in a Bone Marrow Microenvironment.

Naoki Osada, Jiro Kikuchi, Sae Matsuoka

|Jul 02, 2024
Comprehensive analysis of microRNAs modulated by histone deacetylase inhibitors identifies microRNA-7-5p with anti-myeloma effect.

Masahiro Yamada, Sho Ikeda, Wataru Kuroki

|Feb 29, 2024
An observational study of once-weekly carfilzomib in patients with multiple myeloma in Japan (Weekly-CAR study).

Yu Abe, Shiro Kubonishi, Masaki Ri

|Feb 13, 2023
Hypoxia-induced oxidative stress promotes therapy resistance via upregulation of heme oxygenase-1 in multiple myeloma.

Ko Abe, Sho Ikeda, Miho Nara

Pageof 2

Frequent Collaborators

6 joint publications

Naoto Takahashi

5 joint publications

Akihiro Kitadate

2 joint publications

Kentaro Narita

2 joint publications

Kosei Matsue